The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $56 million to fund various clinical research aimed at treating Parkinson’s disease, autoimmune conditions and a variety of cancers. The awards will support seven projects—five clinical trials and two preclinical projects—in the Agency’s clinical program which provides funding for … Continue reading CIRM awards more than $56 million for clinical research aimed at treating Parkinson’s disease, autoimmune conditions and a variety of cancers
CIRM funded research
Neurona Therapeutics Raises $120M Financing, Cell Therapy Shows Positive Outcomes in CIRM-Funded Trial
Photo Courtesy of Neurona Therapeutics/Curtis Myers Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, recently announced the successful completion of a $120 million financing. Neurona’s financial success is an encouraging sign for the stem cell and gene therapy sector, highlighting partnerships with investors and public organizations … Continue reading Neurona Therapeutics Raises $120M Financing, Cell Therapy Shows Positive Outcomes in CIRM-Funded Trial
CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
John A. Zaia, MD, of Beckman Research Institute of City of Hope This year marks the 35th commemoration of World AIDS Day, a global event that aims to end human immunodeficiency virus (HIV) related stigma, honor people lost to the disease, and reaffirm the commitment to ensuring HIV is no longer a public health threat. … Continue reading CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
CIRM invests $50 million in clinical research, including trial for vision loss
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, today awarded $50.1 million to fund clinical-stage research projects aimed at advancing stem cell and gene therapy treatments for a variety conditions ranging from neurodegenerative diseases and blood cancers to HIV/AIDS. The awards will support six projects in the Agency’s … Continue reading CIRM invests $50 million in clinical research, including trial for vision loss
Novartis acquisition validates CIRM’s impact on cystinosis treatment
Dr. Stephanie Cherqui The future looks brighter for cystinosis patients and their families. As one of 7,000 rare diseases, cystinosis causes an abnormal build-up of the amino acid cystine that can lead to organ failure and premature death. With little to no treatment options, children and young adults primarily affected by the condition often have … Continue reading Novartis acquisition validates CIRM’s impact on cystinosis treatment
Apply now! Translational research funding, applications due June 13th
The California Institute for Regenerative Medicine (CIRM) is pleased to announce the next round of funding opportunities for Translational (TRAN) research projects. Click here to access the Program Announcement. The objective of this program is to fund promising stem cell-based and gene therapy projects that accelerate completion of translational stage activities necessary for advancement to clinical study or broad … Continue reading Apply now! Translational research funding, applications due June 13th
California agency invests $4 million in stem cell treatment for Parkinson’s Disease
The California Institute for Regenerative Medicine (CIRM) is investing $4 million in a late-stage preclinical project by Ryne Bio aiming to improve treatment for Idiopathic Parkinson's disease (PD). PD is characterized by a loss of dopamine producing neurons that result in motor symptoms, such as dyskinesias (involuntary, erratic, writhing movements of the face, arms, legs … Continue reading California agency invests $4 million in stem cell treatment for Parkinson’s Disease
Funding development of a vaccine for acute myelogenous leukemia (AML)
Dr. Karin Gaensler. Photo credit: Steve Babuljak/UCSF Adult acute myelogenous leukemia—also known as acute myeloid leukemia (AML)—is a blood cancer in which the bone marrow makes a large number of abnormal blood cells. About 20,000 new cases of AML are diagnosed each year in the US with a 5-year survival rate of around 29%. In … Continue reading Funding development of a vaccine for acute myelogenous leukemia (AML)
CIRM funds clinical trial to make cancer therapy safer, less toxic
Blood stem cell transplantation following high dose chemotherapy is standard of care and potentially curative for aggressive forms of lymphoma. However, this treatment regimen is limited by severe toxicity and life-threatening complications due to delayed recovery of the blood system and vascular related damage of multiple organs. Today the governing Board of the California Institute … Continue reading CIRM funds clinical trial to make cancer therapy safer, less toxic
Tratando malformaciones congénitas antes del nacimiento
El bebé, Tobi recibió un tratamiento de células madre, financiado por el CIRM, mientras aún estaba en el útero. To read this blog in English, click here. Michelle y Jeff se llenaron de felicidad cuando se enteraron de que iban a tener un bebé. Luego, un examen de ultrasonido a las 20 semanas del embarazo … Continue reading Tratando malformaciones congénitas antes del nacimiento